Seeking Alpha

More on Jazz Pharmaceuticals (JAZZ): Q2 beats across the board. Total revenues were $129.5M,...

More on Jazz Pharmaceuticals (JAZZ): Q2 beats across the board. Total revenues were $129.5M, boosted by strong organic growth and the positive impact of the Azur Pharma and EUSA Pharma acquisitions. The company guided FY12 revenues higher, now expecting revenue of $605M - $615M, versus the current consensus of $599.6M.

Check out Seeking Alpha’s new Earnings Center »

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs